EUVIMEDEUVIMED entdecken
Open Access

Early capecitabine metronomic chemotherapy improves patient prognosis and safety in early-stage triple-negative breast cancer

Yumin Sun, Jin Shang, Kenan Duan, Yu Song, Ziyao Yang

American Journal of Translational Research · 2025 · 17 (12) · 9304-9316

DOI: 10.62347/iqtl4270 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Translational Research, 2025. Verfasst von Yumin Sun und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Xi'an People's Hospital (Xi'an No. 4 Hospital) Xi'an 710100, Shaanxi, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To evaluate the effect of different initiation times of capecitabine metronomic chemotherapy on prognosis and safety in patients with early-stage triple-negative breast cancer (TNBC). METHODS: This retrospective study included 206 early-stage TNBC patients treated between March 2018 and January 2022. The patients were divided into early (≤ 4 weeks after surgery, n = 104) and delayed (> 4 weeks, n = 102) initiation groups. Clinical data, laboratory indicators (carcinoembryonic antigen [CEA], carbohydrate antigen 125 [CA125], neutrophil-to-lymphocyte ratio [NLR]), survival, and adverse reactions were compared between the two groups. RESULTS: The early initiation group showed significantly longer 3-year progression-free survival (PFS) (P 0.05). Reductions in CEA, CA125, and NLR were more prominent in the early initiation group (P < 0.05). Subgroup analysis indicated a PFS advantage for T2-stage patients. Adverse reactions, mainly hand-foot syndrome and bone marrow suppression, were comparable between groups, with most cases being grade 1-2. CONCLUSION: Early initiation of capecitabine metronomic chemotherapy can improve the PFS in early-stage TNBC patients, especially for patients with T2 stage, with manageable safety.

Schlagwörter

Stichwörter der Autor:innen

Triple-negative breast cancercapecitabinemetronomic chemotherapyprogression-free survivalsafetytreatment timing

Autor:innen und Institutionen

  • Department of Breast Surgery, Xi'an People's Hospital (Xi'an No. 4 Hospital) Xi'an 710100, Shaanxi, China.
  • Department of Orthopedics, Xi'an People's Hospital (Xi'an No. 4 Hospital) Xi'an 710100, Shaanxi, China.
  • Department of Respiratory Medicine, Xi'an People's Hospital (Xi'an No. 4 Hospital) Xi'an 710100, Shaanxi, China.

Zitieren

APA

Sun, Y., Shang, J., Duan, K., Song, Y., & Yang, Z. (2025). Early capecitabine metronomic chemotherapy improves patient prognosis and safety in early-stage triple-negative breast cancer. American Journal of Translational Research, 17(12), 9304-9316. https://doi.org/10.62347/iqtl4270

Vancouver

Sun Y, Shang J, Duan K, Song Y, Yang Z. Early capecitabine metronomic chemotherapy improves patient prognosis and safety in early-stage triple-negative breast cancer. American Journal of Translational Research. 2025;17(12):9304-9316. doi:10.62347/iqtl4270

BibTeX
@article{Sun2025,
  author = {Sun, Yumin and Shang, Jin and Duan, Kenan and Song, Yu and Yang, Ziyao},
  title = {Early capecitabine metronomic chemotherapy improves patient prognosis and safety in early-stage triple-negative breast cancer},
  journal = {American Journal of Translational Research},
  year = {2025},
  volume = {17},
  number = {12},
  pages = {9304--9316},
  doi = {10.62347/iqtl4270}
}
Kostenlos starten →